These observations suggest that monotreme GLP-1 peptides may have gained new as yet undefined functions
One reason topical GHK-Cu efficacy varies so much between users is that the peptide struggles to penetrate intact skin
Though this procedure is fast and provides quick results, its invasive and comes with risks like scarring, infection, and uneven/lumpy results
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
Although the disease-specific effects differ across PCOS, endometriosis, leiomyomas, POI, endometritis, and gynecologic cancers, these pathological states share overlapping signaling disturbances
This action is especially important for people with Type 2 diabetes, whose pancreas does not produce enough insulin
